Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc.

OBIO·NASDAQ

$3.86

-0.52%
HealthcareBiotechnology

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$231.14M
EPS-1.1100
P/E Ratio-3.48
Earnings Date08/11/2026

No Dividend Yield Data

OBIO has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

OBIO has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

OBIO has not reported any net dividends paid values in the available annual periods.

Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. Dividend History

OBIO · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

OBIO Dividend Payment History

OBIO · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
obio

Orchestra BioMed Holdings, Inc. Payout Ratio Analysis

OBIO · NASDAQ
Dividends Paid
0.00
2025
Net Income
-52.95M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.